Related Experiment Video
Updated: Jun 14, 2025
07:36
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
Published on: June 12, 2021
6.4K
Infiltrating treg reprogramming in the tumor immune microenvironment and its optimization for immunotherapy
Zhaokai Zhou1,2, Jiaxin Xu1,3, Shutong Liu1
1Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
Biomarker Research
|September 3, 2024
Summary
Targeting tumor-infiltrating regulatory T cells (Tregs) offers a novel cancer immunotherapy strategy. Reprogramming these cells within the tumor microenvironment enhances anti-tumor immunity without systemic autoimmune side effects.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Immunotherapy shows promise against tumors but faces challenges from the immunosuppressive tumor immune microenvironment (TIME).
- Infiltrating regulatory T cells (Tregs) significantly contribute to TIME immunosuppression, hindering anti-tumor immune responses.
- Systemic Treg depletion/inhibition boosts anti-tumor immunity but causes detrimental autoimmune effects.
Purpose of the Study:
- To review emerging strategies for targeting tumor-infiltrating (TI)-Tregs.
- To discuss the reprogramming of TI-Tregs to enhance anti-tumor immunity.
- To explore the utilization of Treg reprogramming knowledge for novel cancer immunotherapies.
Main Methods:
- Literature review of current research on TI-Treg targeting strategies.
- Analysis of Treg reprogramming mechanisms within the tumor microenvironment.
- Synthesis of findings to propose novel immunotherapy approaches.
Main Results:
- Emerging strategies focus on reprogramming TI-Tregs rather than systemic depletion.
- Reprogramming TI-Tregs can enhance anti-tumor immunity while mitigating autoimmune risks.
- Understanding Treg regulatory mechanisms is key to developing effective therapies.
Conclusions:
- Targeting TI-Tregs represents a promising avenue for cancer immunotherapy.
- Reprogramming TI-Tregs offers a potential strategy to overcome tumor-induced immunosuppression.
- Further research into Treg reprogramming mechanisms can lead to improved cancer treatments.
Related Concept Videos
01:27Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
01:24T Cell Types and Functions
963
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
963